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MerTK, a receptor tyrosine kinase (RTK) of the TYRO3/AXL/MerTK family, is expressed in myeloid lineage 
cells in which it acts to suppress proinflammatory cytokines following ingestion of apoptotic material. Using 
syngeneic mouse models of breast cancer, melanoma, and colon cancer, we found that tumors grew slowly and 
were poorly metastatic in MerTK–/– mice. Transplantation of MerTK–/– bone marrow, but not wild-type bone 
marrow, into lethally irradiated MMTV-PyVmT mice (a model of metastatic breast cancer) decreased tumor 
growth and altered cytokine production by tumor CD11b+ cells. Although MerTK expression was not required 
for tumor infiltration by leukocytes, MerTK–/– leukocytes exhibited lower tumor cell–induced expression of 
wound healing cytokines, e.g., IL-10 and growth arrest-specific 6 (GAS6), and enhanced expression of acute 
inflammatory cytokines, e.g., IL-12 and IL-6. Intratumoral CD8+ T lymphocyte numbers were higher and lym-
phocyte proliferation was increased in tumor-bearing MerTK–/– mice compared with tumor-bearing wild-type 
mice. Antibody-mediated CD8+ T lymphocyte depletion restored tumor growth in MerTK–/– mice. These data 
demonstrate that MerTK signaling in tumor-associated CD11b+ leukocytes promotes tumor growth by damp-
ening acute inflammatory cytokines while inducing wound healing cytokines. These results suggest that inhi-
bition of MerTK in the tumor microenvironment may have clinical benefit, stimulating antitumor immune 
responses or enhancing immunotherapeutic strategies.
Introduction
MerTK is a member of a receptor tyrosine kinase (RTK) family 
that also includes AXL and TYRO3. Family members undergo 
ligand-induced homodimerization, followed by catalytic tyrosine 
kinase activation and intracellular signaling (1–4). Cross-phospho-
rylation has also been demonstrated within this RTK family, sug-
gesting heterodimerization (5). These RTKs are widely expressed 
in many epithelial tissues and in cells of the immune, nervous, and 
reproductive systems (2, 6). The MerTK ligands include growth 
arrest-specific 6 (GAS6) (7, 8), protein-S (9, 10), tubby and tubby-
like protein-1 (TULP1) (11), and galectin-3 (12). Several of these 
ligands are present in serum, and all are expressed locally in some 
tissues. These ligands bind to the extracellular domain of MerTK, 
resulting in tyrosine kinase activation.
With respect to neoplastic diseases, MerTK is expressed in non-
neoplastic cells found in the tumor microenvironment. MerTK is 
also ectopically expressed or overexpressed in many hematologic 
and epithelial malignant cells. Moreover, expression of MerTK 
and GAS6 correlates with poor prognosis or chemoresistance 
in some human tumor types (1, 2, 13–19). However, the mecha-
nisms by which increased MerTK signaling contributes to tumor 
malignancy remain unknown.
Studies using mice devoid of MerTK revealed its critical role at 
the interface of innate and adaptive immunity (4, 20, 21). Innate 
immunity requires rapid and robust activation in response to 
pathogens or wounding. However, this response must be restrained 
to prevent inflammation-associated tissue damage or immunity 
against self-antigens. MerTK signaling plays a central role in damp-
ening the innate immune response in DCs and macrophages (21). 
One mechanism by which MerTK performs this task is through 
efferocytosis, the physiological process by which apoptotic cells 
are engulfed by phagocytes (22). MerTK ligands, including GAS6, 
simultaneously bind to MerTK expressed on phagocytes and to 
phosphatidylserine presented on the outer plasma membrane leaf-
lets of apoptotic cells (23, 24). This complex ligand (GAS6 bound to 
externalized phosphatidylserine) activates MerTK tyrosine kinase 
signaling, initiates phagocytosis of apoptotic material, and drives 
transcriptional changes that cause suppression of proinflamma-
tory cytokines, such as IL-12, and increases in inflammatory repres-
sors, such as IL-10 (25, 26). Therefore, MerTK-mediated efferocyto-
sis is necessary to maintain tissue homeostasis in organs harboring 
abundant apoptotic materials, such as the retina and the postlac-
tational mammary gland (27, 28).
MerTK similarly dampens TLR-induced production of proin-
flammatory cytokines, such as IL-6, IL-12, and type I interferons 
(IFNs), which fail to be downregulated in MerTK–/– mice (4, 24, 
29). For example, low doses of lipopolysaccharide in MerTK–/– mice 
resulted in death from endotoxic shock associated with high levels 
of TNF-α (30). Failure to dampen acute innate immunity leads to 
secondary pathological activation of T and B lymphocytes directed 
at self-antigens (4, 26, 29, 31, 32). This is especially important 
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given that apoptotic cells accumulate in the absence of MerTK 
(23, 28), providing an enriched source for intracellular “self” anti-
gens in the context of heightened acute inflammatory signals and 
enhanced B and T lymphocyte activity. Therefore, MerTK signal-
ing on macrophages and DCs lies at the interface of the innate and 
adaptive immune systems. Combined loss of MerTK, AXL, and 
TYRO3 results in a highly active autoimmune state, with massive 
lymphocyte proliferation and lupus-like autoimmunity (33).
Numerous studies indicate that tumor-associated macrophages 
correlate with a poor prognosis in patients with cancer (34–36). 
Reduction of macrophage presence in mouse models of breast 
cancer by genetic loss of CSF1, or by antibody-mediated blockade 
of CSF1 receptor signaling, substantially reduced tumor metas-
tasis (37, 38), demonstrating that malignant tumor progression 
is promoted by macrophages. Tumor-associated macrophages 
generally secrete wound healing cytokines that increase growth of 
epithelial tumor and stromal cells in experimental models (39–41). 
Tumor-associated macrophages also pro-
duce immune-modulating cytokines such 
as IL-10, which may decrease antitumor 
immunity by suppressing proinflamma-
tory cytokine expression, limiting antigen 
presentation, and dampening of T lym-
phocyte–mediated tumor cell cytotoxicity 
(41, 42). For example, antigen presen-
tation in the context of increased IL-12 
results in clonal expansion of CD8+ T lym-
phocytes (43); the suppression of IL-12 in 
the tumor microenvironment suggests a 
mechanism by which tumor-associated 
macrophage-mediated changes in antigen 
presentation and cytokine production 
may directly decrease T cell–mediated 
antitumor immunity.
Interestingly, the characteristically low 
IL-12/high IL-10 production observed 
in tumor-associated macrophages is also 
seen in macrophages and DCs following 
efferocytosis. Because MerTK appears to 
be a central regulator of the transition 
from proinflammatory to wound healing 
cytokine production following efferocyto-
sis, and because MerTK-deficient macro-
phages produce increased proinflamma-
tory cytokines, we tested the hypothesis 
that MerTK in the tumor microenviron-
ment aids malignant tumor progression 
by suppressing antitumor immunity. We 
show here that loss of MerTK in the tumor 
microenvironment of MerTK–/– mice (30) 
slowed the establishment, growth, and 
metastasis of mammary tumors and mel-
anomas in immune competent, syngeneic 
mice. These findings were recapitulated in 
spontaneous mammary tumors in recipi-
ents of MerTK–/– bone marrow transplants. 
Very early immune responses to syngeneic 
tumor cell implantation in MerTK–/– mice 
included decreased IL-10 and increased 
IL-12 production, increased leukocyte 
proliferation, and a higher level of tumor CD8+ T lymphocytes as 
compared with early tumor-induced responses in MerTK+/+ mice. 
Isolation of CD11b+ cells from tumors revealed MerTK-depen-
dent repression of proinflammatory cytokines. Antibody-based 
depletion of CD8+ T lymphocytes restored tumor growth in 
MerTK–/– hosts. These results suggest that MerTK in the immune 
compartment of the tumor microenvironment suppresses innate 
immunity and promotes tumor progression. They also suggest 
that inhibition of MerTK signaling may produce an immunomod-
ulatory, therapeutic benefit in some human tumors.
Results
Prolonged tumor latency and decreased metastasis in MerTK–/– hosts. To 
determine whether host-derived MerTK in the tumor microen-
vironment affects tumor formation and growth, primary mouse 
mammary tumor cells derived from female MMTV-PyVmT mice 
(43) (inbred into the C57BL/6 genetic background) were injected 
Figure 1
Decreased tumor malignancy in MerTK–/– microenvironment. (A) MMTV-PyVmT mammary tumor 
cells injected into the mammary fat pads and B16:F10 tumor cells injected intradermally formed 
tumors with a delayed latency in MerTK–/– mice as compared with that in MerTK+/+ and MerTK+/– 
mice. P values comparing MerTK+/+ to MerTK–/– were determined using the log-rank (Mantel-Cox) 
test. (B) H&E-stained sections of tumors harvested 30 days after tumor cell injection in MerTK+/+ 
mice and 180 days after tumor cell injection in MerTK–/– mice. Boxed regions are shown at higher 
magnification below and indicate the monotonous sheets of tumor cells in MerTK+/+ mice and the 
compartmentalized nature of the implanted tumor cells in MerTK–/– mice. Original magnification, 
×100 (top row); ×600 (bottom row). (C) Lung metastases were enumerated in tumor-bearing 
mice at 14 days after MMTV-PyVmT tumor palpation (n = 14–16), at 7 days after B16:F10 tumor 
palpation (n = 5), and at 7 days after MC38 tumor palpation of subcutaneously implanted MC38 
cells. Horizontal bars represent average numbers of lung metastases per mouse. P values were 
calculated using Student’s t test for MMTV-PyVmT tumors (comparing MerTK+/+ to MerTK–/–) 
and using a 1-tailed Mann-Whitney test for B16:F10 and MC38 tumors. *P < 0.05. ***P < 0.001.
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orthotopically into the inguinal mammary fat pads of female 
wild-type (MerTK+/+) and MerTK–/– recipient mice. While tumors 
formed in MerTK+/+ mice with an average latency of 28 days, latency 
was delayed in MerTK–/– littermates (P < 0.001). Tumors remained 
unpalpable in 70% of MerTK–/– mice throughout the entire study 
period of 198 days (Figure 1A). Mice carrying one functional MerTK 
allele (MerTK+/– mice) formed tumors with an average latency of 49 
days, which was intermediate between MerTK+/+ mice (P < 0.001) 
and MerTK–/– mice (P < 0.001, Mantel-Cox test). This suggests that 
MerTK signaling in the stromal environment enhances tumor 
growth in a dose-dependent man-
ner. C57BL/6-derived B16:F10 
mouse melanoma cells injected 
orthotopically formed intrader-
mal tumors in MerTK+/+ mice 
with an average latency of 26 
days, compared with 48 days in 
MerTK–/– littermates (P < 0.0001; 
Figure 1A). Similarly, a third syn-
geneic model demonstrated pro-
longed latency. C57B1/6 MC38 
colon cancer cells were implanted 
subcutaneously; in MerTK+/+ mice 
tumors formed with an average 
latency of 27 days as compared 
with 46 days in MerTK–/– mice 
(P < 0.0001, data not shown).
Histological analysis of MMTV-
PyVmT tumors that formed in 
MerTK–/– mice revealed distinct 
differences from those growing in 
MerTK+/+ mice. Tumors harvested 
from MerTK+/+ mice displayed 
densely packed solid sheets of 
cells, with prominent hyperchro-
matic nuclei and little cytoplasm, 
regions of central necrosis, and 
invasion into skeletal muscle (Fig-
ure 1B). In contrast, tumors har-
vested from MerTK–/– mice were 
small and harbored more connec-
tive tissue as opposed to the frank 
cellularity of tumors in MerTK+/+ 
hosts (Figure 1B). MerTK–/– mice 
were less prone to formation of 
lung metastases (Figure 1C), with 
only 3 out of 15 MerTK–/– mice 
presenting with lung micrometas-
tases derived from MMTV-PyVmT 
primary tumors, as compared 
with 13 out of 15 wild-type mice 
and 16 out of 17 MerTK+/– mice 
exhibiting MMTV-PyVmT lung 
metastases. Lung metastases were 
not detected in any MerTK–/– mice 
bearing B16:F10 tumors, while 3 
out of 5 wild-type mice displayed 
B16:F10 lung metastases. Like-
wise, 4 out of 5 subcutaneously 
implanted MC38 colon cancer 
cell tumors in MerTK+/+ mice yielded lung metastases, whereas none 
were detected in the MerTK–/– mice (Figure 1C). These data suggest 
that MerTK signaling in the tumor microenvironment leads to 
increased tumor growth and malignant progression.
MerTK–/– leukocytes confer tumor resistance in MerTK+/+ mice. 
There are complex autocrine and paracrine interactions between 
tumor-associated macrophages and the epithelial cells in preclin-
ical breast cancer models and presumably in human breast can-
cer. These have been well characterized in the polyoma middle 
T model. To rule out a potential role of MerTK in our C57/Bl6 
Figure 2
MerTK-deficient leukocytes confer tumor resistance to MerTK+/+ mice. (A) Whole cell lysates harvested 
from MMTV-PyVmT primary mammary tumor cells were assessed by Western analysis using antibodies 
indicated. Whole spleen lysates harvested from MerTK+/+ and MerTK–/– mice were used as positive and 
negative controls, respectively, for MerTK expression. Whole spleen lysates harvested from MerTK+/+ 
mice were used as a positive control for AXL expression. Whole brain lysates harvested from Tyro3+/+ and 
Tyro3–/– mice were used as positive and negative controls from TYRO3 expression. (B–D) Bone marrow 
harvested from MerTK+/+ or MerTK–/– donors was delivered by tail vein injection into lethally irradiated 
6-week-old female MMTV-PyVmT recipients. (B) Average tumor volume ± SEM measured in live mice 
by MRI at 15.8, 17.8, and 19.8 weeks of age. (C) Representative transverse MRI slices of age-matched 
MMTV-PyVmT recipients of MerTK+/+ or MerTK–/– bone marrow in the lower abdomen/pelvic region. The 
arrows indicate the location of the spine, while the tumor (T) margins are identified by the red dotted line. 
(D) Total tumor weight measured at 21 weeks of age (time of necropsy). Horizontal bars represent average 
total tumor weight ± SEM (n = 14). The P value was calculated using Student’s t test. *P < 0.05. (E) Mam-
mary fibroblasts harvested from MerTK+/+ and MerTK–/– mice were cotransplanted with MMTV-PyVmT 
tumor cells into the mammary fat pads of MerTK+/+ mice, and tumor latency was measured.
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PyVmT cells, we measured MerTK protein expression by Western 
analysis. Protein lysates from cultured tumor cells did not express 
MerTK. MerTK was detected in whole spleen lysates harvested 
from MerTK+/+ mice but not MerTK–/– mice (Figure 2A). Certain 
paracrine ligands (e.g., GAS6) might bind to other members of 
this RTK family in PyVmT cells; therefore, we examined the pro-
tein expression of AXL and TYRO3. Neither AXL nor TYRO3 were 
expressed in the PyVmT breast cancer cells. qPCR of RNA levels 
confirmed these findings (data not shown).
However, as MerTK is expressed in hematopoietic cells, we used 
bone marrow reconstitution assays to determine the impact of 
MerTK ablation within bone marrow–derived subpopulations of 
the tumor microenvironment. We harvested bone marrow from 
MerTK–/– × UBC-GFP and MerTK+/+ × UBC-GFP donors and deliv-
ered marrow to lethally irradiated 6-week-old C57BL/6 female 
transgenic MMTV-PyVmT mice. After 4 weeks, mice exhibiting 
>75% GFP+ hematopoietic cells were used for further analysis. At 
this time point (10 weeks of age), the majority of mice had already 
developed tumors, consistent with the published average tumor 
latency in this aggressive tumor model (44). Therefore, it was not 
feasible to detect potential differences in tumor latency. Instead, 
tumor growth was measured by MRI over the following 11 weeks, 
revealing reduced tumor volume in MerTK–/– bone marrow recip-
ients as compared with that in MerTK+/+ bone marrow recipients 
(Figure 2, B and C). Similarly, upon sacrifice at the study end 
point (21 weeks of age), total tumor weight was decreased nearly 
2 fold in MerTK–/– bone marrow recipients as compared with that 
in MerTK+/+ bone marrow recipients (Figure 2D). To measure the 
burden of apoptotic material in these tumors, immunofluorescent 
detection of apoptotic cells by TUNEL analysis in these late-stage 
tumors (19.8 weeks of age) was performed. The number of apop-
totic tumor cells within F4/80+ macrophages was not altered in 
recipients of MerTK–/– bone marrow as compared to what was seen 
in tumors harvested from MerTK+/+ bone marrow recipients (Sup-
plemental Figure 1; supplemental material available online with 
this article; doi:10.1172/JCI67655DS1).
Because bone marrow–derived mesenchymal stem cells might 
give rise to fibroblasts in the tumor microenvironment that could 
modulate tumor growth and metastasis (45), we investigated the 
impact of MerTK–/– fibroblasts in the tumor microenvironment. 
106 mammary fibroblasts harvested from MerTK–/– and MerTK+/+ 
donors were cotransplanted with MMTV-PyVmT tumor cells into 
MerTK+/+ mammary fat pads. The rate of tumor formation was sim-
ilar in mice receiving MerTK–/– or MerTK+/+ fibroblasts (Figure 2E). 
Together, these data suggest that loss of MerTK from the immune 
compartment, but not the fibroblast compartment, of the tumor 
microenvironment is sufficient to delay tumor formation.
Altered early tumor response in MerTK–/– mice. To examine early 
immune response in the tumor microenvironment, inguinal 
mammary glands were harvested 4 days after MMTV-PyVmT tumor 
inoculation. At this time, tumor cells were evident in the injected 
mammary glands of both MerTK+/+ and MerTK–/– mice, as shown 
in H&E-stained sections and by immunohistochemical detection 
of pan-cytokeratin (Figure 3A). However, higher-power magnifi-
cation of the injection site revealed histological differences at this 
early stage, including an abundance of matrix deposition and 
reduced tumor cellularity in MerTK–/– samples as compared with 
that in MerTK+/+ samples (Figure 3A). After removal of the intra-
mammary lymph node, mammary cell suspensions were stained 
with antibodies against CD11b and CD11c to identify tumor- 
recruited macrophages and DCs. To control for injection-induced 
changes in the cell populations, we injected sterile phospho- 
buffered saline (PBS) into the contralateral mammary fat pads. The 
results revealed that, in early-stage implanted tumors, there are 
differences in basal macrophage and DC levels in MerTK–/– mam-
mary glands as compared with those in MerTK+/+ mammary glands 
(Figure 3B). At 4 days after tumor inoculation into the mammary 
gland, the percentages of macrophages and DCs were relatively 
unchanged in MerTK+/+ mice as compared to those in PBS-injected 
MerTK+/+ mice. In contrast, tumor cell injection in MerTK–/– fat pads 
generated a >4-fold increase in macrophages and >3.5-fold increase 
in DCs over PBS-injected MerTK–/– mammary glands.
RNA isolated from single cell mammary suspensions harvested 
at 4 days after tumor (or PBS) inoculation revealed increased tran-
script levels encoding the wound healing/tolerogenic cytokine IL-10 
in MerTK+/+ samples but not in MerTK–/– samples (Figure 3C). Con-
versely, transcripts encoding the proinflammatory cytokine IL-12 
were elevated 10 fold at 4 days after MMTV-PyVmT tumor cell inoc-
ulation in MerTK–/– mice but not in MerTK+/+ mice. We similarly 
assessed Il10 and Il12 mRNA levels 4 days following implantation 
of B16:F10 mouse melanoma cells into the mouse mammary fat 
pad. Tumor-recruited cells were collected 4 days after tumor cell 
injection. Il10 transcript levels were substantially increased in sam-
ples from tumor cell–inoculated MerTK+/+ mice as compared with 
those from PBS-inoculated MerTK+/+ mice. However, Il10 transcript 
levels were unchanged in cells harvested from tumor cell–inoculated 
MerTK–/– mice (Figure 3C). While Il12 transcript levels remained rel-
atively unchanged in MerTK+/+ cells harvested from PBS- and tumor 
cell–treated mice, cells harvested from MerTK–/– mice expressed more 
Il12 transcripts 4 days after tumor cell injection as compared with 
4 days after PBS injection (Figure 3C). Serum IL-12p70 and IL-6 lev-
els were increased 4 days after intramammary MMTV-PyVmT tumor 
cell injection into MerTK–/– mice, but not MerTK+/+ mice, over what 
was seen in PBS-injected MerTK–/– and MerTK+/+ mice, respectively 
(Figure 3D). Mammary fat pad injection of B16:F10 tumor cells 
also generated increased serum IL-12p70 and IL-6 levels in MerTK–/– 
mice (Figure 3D). We repeated this analysis 4 days after injection of 
B16:F10 tumor cells i.p. into MerTK+/+ and MerTK–/– mice, yielding 
Figure 3
Altered early tumor response in MerTK-deficient mice. (A) Repre-
sentative H&E-stained and cytokeratin-stained sections of mammary 
glands 4 days after injection with MMTV-PyVmT cells are shown. Boxed 
regions are shown at higher magnification below. Original magnifica-
tion, ×100 (top row); ×600 (bottom rows). (B) Single cell mammary sus-
pensions harvested 4 days after intramammary tumor cell injections 
were stained for CD11b and CD11c. Proportions of CD11b+CD11c– 
macrophages and CD11b+CD11c+ dendritic cells relative to total PBS-
treated MerTK+/+ CD11b+CD11c+ population is shown. *P < 0.05. (C) 
RNA harvested 4 days after PBS, MMTV-PyVmT, or B16:F10 injection 
into the inguinal mammary fat pad was assessed by qPCR to detect 
IL-10 and IL-12p40 transcripts. (D) Serum collected 4 days after injec-
tion of PBS, MMTV-PyVmT, or B16:F10 tumor cells into the inguinal 
mammary fat pad was assessed by ELISA to measure IL-12p70 and 
IL-6. (C and D) Values shown, calculated using the (C) δδCT method 
or (D) serum levels, represent the average ± SD (n = 6), relative to the 
level detected in PBS-treated MerTK+/+ samples. *P < 0.05; **P < 0.01; 
***P < 0.001. (E) Mice were inoculated with B16:F10 cells by i.p. injec-
tion. After 4 days, mice were treated with BrdU. Splenocytes harvested 
after 1 hour treatment with BrdU were stained with anti-BrdU and pro-
pidium iodide and assessed by flow cytometry.
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Figure 4
Altered cytokine production in MerTK–/– tumor microenvironment. (A and B) Immunohistochemistry for (A) F4/80 and (B) MerTK in tumors from 
(A) MerTK+/+ and MerTK–/– mice and (B) MerTK+/+ mice. Original magnification, ×400 (A); ×600 (B). (C) Single cell MMTV-PyVmT tumor suspen-
sions harvested from MerTK+/+ (solid line) and MerTK–/– (tinted area) mice were stained for CD45 and F4/80. Representative plots for live cells 
are shown. Average ± SEM; n = 4. (D) Total RNA harvested 4 days after PBS, MMTV-PyVmT, or B16:F10 injection was assessed by qPCR for 
Gas6 and Mfge8. δδCT values shown represent average ± SD (n = 6) relative to PBS-injected MerTK+/+ values. **P < 0.01. (E) Serum IL-12p70 
was measured by ELISA in serum harvested 3–4 weeks after tumor cell inoculation (n = 13). **P < 0.01. (F and G) CD11b+ cells were harvested 
from MMTV-PyVmT tumors (F) 8 weeks and (G) 15 weeks after bone marrow transplant. GFP+CD45+CD11b+ cells were purified from tumors and 
cell lysates were analyzed by cytokine array. *P < 0.05.
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similar results. Cells harvested by peritoneal lavage were used to 
assess expression of transcripts encoding IL-10 and IL-12. Il10 tran-
scripts were elevated in cells isolated from MerTK+/+ mice inoculated 
with B16:F10 cells by i.p. injection as compared with those in cells 
from MerTK+/+ mice inoculated with PBS (Supplemental Figure 2). 
In contrast, Il10 transcripts were not elevated in MerTK–/– mice inoc-
ulated with B16:F10 cells. Elevated Il12 transcripts were observed in 
peritoneal lavage cells harvested from tumor-inoculated MerTK–/– 
mice as compared with what was seen in PBS-inoculated mice or 
tumor-inoculated MerTK+/+ mice. Serum IL-6 was also elevated in 
MerTK–/– mice inoculated i.p. with B16:F10 tumor cells (Supple-
mental Figure 2). We used the B16:F10 i.p. inoculation model to 
assess splenocyte proliferative activity. BrdU labeling of mice for 
1 hour, 4 days after i.p. tumor cell or PBS inoculation, revealed that 
BrdU incorporation into splenocytes was similar in MerTK+/+ and 
MerTK–/– mice inoculated with sterile PBS and that BrdU incorpora-
tion increased in both MerTK+/+ and MerTK–/– splenocytes harvested 
4 days after i.p. tumor cell injection as compared with splenocytes 
from PBS-injected, genotype-matched mice (Figure 3E). However, 
the tumor-induced increase in BrdU-positive splenocytes was sub-
stantially greater in MerTK–/– mice compared with that in tumor-
treated MerTK+/+ mice, suggesting that tumor-induced leukocyte 
proliferation was exaggerated in the absence of MerTK.
Altered tumor microenvironment in established tumors in MerTK+/+ and 
MerTK–/– mice. Immunohistochemical detection of F4/80, a mac-
rophage marker, demonstrated macrophage infiltration of ortho-
topic MMTV-PyVmT tumors grown in MerTK+/+ and MerTK–/– mice 
(Figure 4A). MerTK staining was detected in B16:F10 and MMTV-
PyVmT tumor macrophages grown in MerTK+/+ mice (Figure 4B). 
To verify that MerTK–/– macrophages were capable of infiltrating 
spontaneously forming tumors, we generated single cell suspen-
sions from MMTV-PyVmT mice harboring MerTK–/– and MerTK+/+ 
immune cells and stained cell suspensions for CD45, a cell surface 
marker of leukocytes, and F4/80. MerTK+/+ and MerTK–/– CD45+ 
leukocytes were detected at similar proportions of the total cell 
population (Figure 4C), revealing similar levels of CD45+ tumor 
leukocytes and comparable levels of MerTK+/+ and MerTK–/– 
tumor-associated macrophages in these established tumors.
Transcripts encoding the MerTK ligand, GAS6, were identified 
by qRT-PCR in RNA isolated from mammary glands 4 days after 
MMTV-PyVmT tumor cell injection into the mammary fat pads 
of MerTK+/+ and MerTK–/– mice. Gas6 levels in MerTK+/+ mammary 
glands were >3-fold higher in tumor cell–injected glands as com-
pared with those seen in the contralateral PBS-injected mammary 
gland, suggesting that GAS6 is elevated in the tumor microen-
vironment within 4 days (Figure 4D). Increased Gas6 mRNA lev-
els were also detected in MerTK+/+ samples harvested 4 days after 
B16:F10 cell inoculation, consistent with previous reports of 
elevated Gas6 levels in the tumor microenvironment (46). How-
ever, Gas6 remained unchanged in the MerTK–/– mice after tumor 
cell inoculation with MMTV-PyVmT or B16:F10 cells. Because the 
MerTK–/– tumor microenvironment did not induce Gas6 expres-
sion, it is possible that MerTK signaling may be part of the mecha-
nism by which tumors upregulate GAS6 in the microenvironment. 
MFGE8 encodes another phosphatidylserine-interacting ligand 
used for efferocytosis by macrophages (47). Similar to Gas6, Mfge8 
transcript levels were elevated in response to tumors in MerTK+/+ 
but not MerTK–/– samples (Figure 4D).
Cytokine expression in the microenvironment of established 
tumors was examined to determine whether the cytokine expres-
sion patterns seen 4 days after tumor cell injection were sustained. 
Serum IL-12p70 was measured 3–4 weeks after mammary fat pad 
injection of MMTV-PyVmT tumor cells. As compared with that in 
tumor-bearing MerTK+/+ mice, serum IL-12p70 was increased in 
tumor-bearing MerTK–/– mice (Figure 4E), confirming that MerTK 
signaling in the tumor microenvironment suppresses proinflam-
matory cytokine production in both early and late stages of tumor 
progression. To specifically assess MerTK-dependent cytokine 
modulation in macrophages and DCs in the tumor microenviron-
ment, we harvested CD11b+ cells from transgenic MMTV-PyVmT 
mice 8 weeks after lethal irradiation and bone marrow trans-
plantation from MerTK+/+ or MerTK–/– donors. Protein lysates 
from CD11b+ cells were assessed by cytokine array, revealing 
increased levels of IL-1β, IL-6, and IL-12p40 in tumor-associated 
MerTK–/– CD11b+ cells as compared with levels seen in MerTK+/+ 
CD11b+ cells (Figure 4F). CD11b+ cells from transgenic MMTV-
PyVmT mice harvested 15 weeks after bone marrow transplant 
revealed significantly elevated IL-6 levels in MerTK–/– tumor-as-
sociated CD11b+ cells (Figure 4G). M1- and M2-programmed 
tumor-associated F4/80+ macrophages were identified in situ 
using antibodies against inducible nitric oxide synthase (iNOS) 
and arginase-1 (Arg1), respectively. These results confirmed that 
the density of macrophages in the tumor microenvironment was 
relatively similar in tumors grown in MerTK+/+ or MerTK–/– bone 
marrow recipients. Recipients of MerTK–/– bone marrow showed 
a modest decrease in the ratio of M2 to M1 tumor-associated 
macrophages as compared with what was seen in tumors har-
vested from MerTK+/+ bone marrow recipients, although this trend 
was not statistically significant (Supplemental Figure 3). Taken 
together, these data demonstrate that targeted loss of MerTK from 
tumor-associated CD11b+ cells increases and sustains expression 
of proinflammatory cytokines, suggesting that MerTK signaling 
within tumor-associated monocyte-derived cells limits the expres-
sion of proinflammatory cytokines.
CD8+ T lymphocytes are more abundant in the MerTK–/– tumor micro-
environment. Four days after MMTV-PyVmT tumor cell inoculation 
into the mammary fat pad, mammary lymph nodes were removed 
and the remaining tissue was used to generate single cell suspen-
sions. Staining for CD8 and CD4 revealed that the total CD8+CD4– 
population was decreased in tumor-inoculated MerTK+/+ sam-
ples (Figure 5A) but remained unchanged in tumor-inoculated 
MerTK–/– mice. Because NK cells express MerTK and also express 
CD8, we measured the relative presence of NK cells in the early 
tumor microenvironment by staining the CD8+CD4– population 
with NK1.1. Although a slight increase in NK1.1+CD8+CD4– lev-
els was observed in tumor-inoculated MerTK+/+ mice, this did 
not reach statistical significance (Figure 5B). Similar levels were 
seen in MerTK–/– mice treated with either PBS or with tumor 
cells. While these results do not rule out the impact of MerTK on 
tumor-infiltrating NK cell behavior, these data suggest that NK 
cell numbers are not greatly affected in the early tumor microen-
vironment by MerTK. Immunohistochemical detection of gran-
zyme B was used to detect cytotoxic leukocytes (such as CD8+ 
T lymphocytes, NK cells, or NKT cells) in the tumor microenvi-
ronment of MMTV-PyVmT tumors 3–8 weeks after tumor trans-
plant. Granzyme B–positive cells were more abundant in tumors 
grown in MerTK–/– mice as compared with those in tumors grown 
in MerTK+/+ littermates (Figure 5C). In contrast to what was seen 
with the CD8+CD4– population (Figure 5A), we found an early 
tumor-elicited increase in the CD8–CD4+ population in MerTK+/+ 
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mice but a slight decrease in MerTK–/– mice (Figure 5D). We fur-
ther examined this population for expression of CD25 to iden-
tify Tregs. Similar basal levels of CD4+CD25+ cells were identified 
4 days after PBS injection into MerTK+/+ and MerTK–/– mice (Figure 
5E). Although levels of CD4+CD25+ cells increased in response to 
tumors, the increase was similar in MerTK+/+ and MerTK–/– mice.
Depletion of CD8+ T lymphocytes restores tumor growth in MerTK–/– 
mice. CD8+ T lymphocytes were depleted from MerTK+/+ and 
MerTK–/– mice using antibodies against CD8. Mice were pre-
treated with anti-CD8 for 1 week prior to MMTV-PyVmT tumor 
inoculation into mammary fat pads, and antibody treatment was 
maintained for 3 weeks following tumor inoculation. Tumor cell 
suspensions were stained with antibodies against CD4 and CD8, 
revealing decreased presence of CD8+CD4– cells in the tumor 
microenvironment of mice treated with anti-CD8 antibody, as 
compared with those treated with isotype-matched antibody con-
trol (Figure 5F). Histological examination revealed that, while 
MerTK–/– mice treated with the isotype control antibody devel-
oped small tumors comprising primarily matrix and stromal cells 
(Figure 5G), MerTK–/– mice treated with anti-CD8 antibodies devel-
oped larger, more aggressive tumors, with densely packed tumor 
epithelial cells, closely resembling the histological appearance of 
tumors grown in MerTK+/+ mice (Figure 5G). Tumors grown in 
MerTK–/– mice were nearly 3-fold larger upon CD8 depletion as 
compared with those grown in IgG2a-treated MerTK–/– mice (Fig-
ure 5H). These data suggest that, in the MerTK–/– tumor microen-
vironment, CD8+ T lymphocytes are, at least in part, responsible 
for decreased tumor mass.
Discussion
The stromal microenvironment in which a tumor exists greatly 
influences its pathophysiology. Specifically, tumor-associated 
macro phages in human and mouse tumors have been correlated 
with poor prognosis and increased malignant progression. This was 
illustrated by studies in which targeted inhibition of CSF1 receptor 
signaling in tumor-associated macrophages, through gene target-
ing or through antibody-based pharmacologic strategies, decreased 
tumor growth and metastasis in mice (37, 38, 41, 48, 49). Therefore, 
tumor macrophages are valid therapeutic targets. Macrophages and 
DCs can produce the cytokines and growth factors that encourage 
tumor progression and metastasis, such as IL-10, which dampen 
antitumor immune responses (40). We demonstrate here that the 
MerTK+/+ microenvironment responds very rapidly after tumor cell 
implantation by increasing production of IL-10 and GAS6 and 
decreasing production of IL-12. These cytokine changes are cor-
related with a decreased local presence of CD8+ T lymphocytes in the 
tumor. IL-10 and GAS6 induction in the tumor microenvironment 
required MerTK, as tumor-induced IL-10 and GAS6 expression was 
not observed in MerTK-deficient mice. This is consistent with previ-
ous data suggesting that MerTK is required in the innate immune 
system to induce IL-10 following efferocytosis and TLR activation 
(3, 4, 21, 50, 51). We also showed that MerTK-deficient cells in the 
tumor microenvironment express increased IL-12 and IL-6, proin-
flammatory cytokines known to be repressed by MerTK signaling in 
response to efferocytosis or TLR activation (4, 32).
Our results demonstrating upregulation of GAS6 in the tumor 
microenvironment of MerTK+/+ mice are consistent with a previ-
ously published study, demonstrating GAS6 expression in tumor 
macrophages and showing that genetic loss of Gas6 in the micro-
environment of syngeneic tumor transplants decreases tumor 
growth (46). In these studies, GAS6 was not required for tumor 
infiltration by macrophages; this is consistent with our finding 
that tumor-associated macrophage numbers are not altered by loss 
of MerTK. MerTK was needed for full induction of GAS6 in the 
tumor microenvironment, supporting a model in which MerTK 
signaling induces GAS6 expression in tumor macrophages, cre-
ating positive feed-forward signaling through MerTK. Sustained 
MerTK signaling would maintain the repression of proinflamma-
tory cytokines and induce wound healing/tolerogenic cytokines, 
ultimately resulting in decreased antitumor immunity. In the 
PyVmT models, we have demonstrated that the GAS6 receptors 
MerTK, AXL and TYRO3 are absent and, thus, the production or 
lack of production of GAS6 is irrelevant to the tumor cell per se.
Several studies using genetic disruption of MerTK, AXL, and 
TYRO3 in mice demonstrated that the innate immune system 
responds to pathogen-mimicking agents (TLR activation) with an 
early increase in IL-12, IL-6, and type I IFN production, followed 
by MerTK-, AXL-, and TYRO3-dependent reduction of proinflam-
matory cytokine expression, and finally with induction of wound 
healing and tolerogenic cytokines (IL-10, TGF-β) (3, 4, 21, 50, 51). 
In the absence of these receptors, the innate immune system is 
unable to dampen expression of proinflammatory cytokines and 
unable to induce production of tolerogenic cytokines. Similarly, 
we found that early responses of the innate immune system in the 
MerTK+/+ tumor microenvironment were characterized by damp-
ened levels of IL-12 and increased levels of IL-10. However, loss of 
MerTK from the tumor microenvironment caused sustained IL-12 
induction (for up to 14 weeks), without induction of IL-10. There-
fore, it is possible that the innate immune system uses MerTK 
signaling in the tumor microenvironment in a way that parallels 
MerTK function in wounding responses.
Alternatively, MerTK in the tumor microenvironment may 
respond to efferocytosis. Apoptosis occurs in all tissues, and gen-
erally apoptosis rates are higher in rapidly proliferating tumors as 
compared with quiescent tissues. One major physiological role of 
MerTK is to clear apoptotic material through efferocytosis (23). To 
ensure that presentation of self-antigens does not stimulate auto-
immunity following efferocytosis, macrophages suppress IL-12 
production upon efferocytosis and induce IL-10 production (47). 
This limits CD8+ T lymphocyte expansion and reduces antigen 
presentation. It is possible that macrophage-mediated efferocyto-
sis of apoptotic tumor cells drives the cytokine expression patterns 
that characterize tumor-associated macrophages. This scenario, 
Figure 5
Increased presence of CD8+ T lymphocytes in MerTK–/– microenvi-
ronment is required for inhibition of tumor growth. (A and B) Flow 
cytometric analysis of CD8/CD4– and NK1.1+CD8+–stained mam-
mary gland suspensions 4 days after MMTV-PyVmT or PBS injection, 
with quantification (n = 6). (C) Immunohistochemistry for granzyme B. 
Original magnification, ×600. (D and E) Flow cytometry and quantita-
tion of (D) CD8–CD4+ and (E) CD25+CD4+ cells in mammary gland 
suspensions collected 4 days after intramammary injection of tumor 
cells or PBS. (F–H) MMTV-PyVmT tumor cells were injected into mam-
mary fat pads of anti-CD8 antibody–treated mice. Mammary glands/
tumors were collected after 28 days for analysis. (F) CD8/CD4–stained 
tumor suspensions were assessed by flow cytometry. (G) Representa-
tive histological sections are shown. Original magnification, ×200. (H) 
Average MMTV-PyVmT tumor volume at 28 days after inoculation is 
shown ± SD (n = 8). P values were calculated using Student’s t test. 
*P < 0.05; **P < 0.01. 
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mary fat pads, 106 MMTV-PyVmT cells were resuspended in 100 μl sterile 
PBS (in the presence or absence of 0.5 × 106 mouse mammary fibroblasts 
harvested from 6-week-old virgin MerTK+/+ or MerTK–/– female C57BL/6 
mice) and injected centrally in the right no. 4 inguinal fat pad of 6-week-
old virgin mice. For orthotopic injections into the dermis, 103 B16:F10 
melanoma cells were resuspended in 100 μl PBS and injected intrader-
mally between the scapulae of 6-week-old mice. For subcutaneous injec-
tion, 1 × 104 MC38 colon cancer cells were injected into the flank. Tumors 
were detected by manual palpation. Statistical analysis of average tumor 
latency was assessed by log-rank test. Where indicated, i.p. injection of 
3 × 103 B16:F10 cells was performed in 100 μl PBS, and cells were collected 
in MEM by peritoneal lavage after 4 days.
Histological analysis and immunohistochemistry. Tumors and mammary 
glands were harvested and immediately fixed in 10% formalin (VWR Sci-
entific). Paraffin-embedded tumors and mammary glands were sectioned 
(5 μm), rehydrated, and peroxidase-quenched with 3% H2O2. Rehydrated 
slides were stained with H&E by the UNC Lineberger Animal Histopathol-
ogy Core Facility. Immunohistochemistry was performed as previously 
described (55, 56) using the following polyclonal antibodies: F4/80 (6A545, 
Santa Cruz Biotechnology Inc.; diluted 1:200), MerTK (produced by the 
Earp laboratory) against a peptide in the intracellular domain of human 
MerTK; diluted 1:100), pan-cytokeratin (H240, Santa Cruz Biotechnol-
ogy Inc.; diluted 1:500), and granzyme B (Santa Cruz Biotechnology Inc.; 
diluted 1:200). Slides were washed in PBST and then incubated in biotiny-
lated anti-rabbit or anti-rat antibody (Vector Laboratories) and developed 
using the Vectastain Kit (Vector Laboratories). Sections were photographed 
using the Zeiss LCM 210 microscope and Scion Image 2.0 software.
Western blot analysis. MMTV-PyVmT tumor cells were lysed in lysis buf-
fer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM EDTA, 10% glycerol, 
and 1% Triton X-100) supplemented with phosphatase inhibitors (1 mM 
Na3VO4 and 0.1 mM Na2MoO4) and protease inhibitors (Complete Mini, 
Roche Applied Science). Whole spleen lysates harvested from MerTK+/+ and 
MerTK–/– mice and whole brain lysates harvested from Tyro3+/+ and Tyro3–/– 
mice were prepared in sodium chloride–Tris-EDTA buffer and sonicated. 
Whole protein lysates were separated on 8% Tris-glycine SDS-PAGE gels 
(Life Technologies) and then transferred to nitrocellulose membranes 
(iBlot, Life Technologies). Membranes were probed with primary antibod-
ies: anti-mouse MerTK (AF591, R&D Systems; diluted 1:2,000), anti-mouse 
AXL (AF854, R&D Systems; diluted 1:1,000), and anti-TYRO3 rabbit sera 
(produced by the Prieto laboratory; diluted 1:20,000)
Bone marrow transplantation. Six-week-old female MMTV-PyVmT mice were 
lethally irradiated with 9.5 Gy split over 2 doses. 1 × 106 bone marrow cells 
from C57BL/6-Tg(UBC-GFP)30Scha/J (The Jackson Laboratory) MerTK+/+ 
or MerTK–/– donors were delivered to irradiated mice by tail vein injection. 
After 4 weeks, recipient mice that expressed ≥75% GFP in peripheral blood 
indicated successful engraftment and were included for further analysis. 
Animals were housed and experimental procedures were done in accordance 
with the regulatory standards approved by the University of Colorado, 
Anschutz Medical Campus’ IACUC.
Tumor measurement by MRI. Mammary gland tumor growth was mea-
sured over time by MRI. Mice were anesthetized with 1.5% to 2.5% inhaled 
isoflurane and were placed in the 4.7 Tesla Bruker MRI/MRS Pharma Scan. 
Gadolinium-DTPA bismethylamide (gadodiamide, OMNISCAN) was 
administered intravenously as a contrast agent. Axial plane images of the 
animals were obtained using conventional T1-, T2-, and proton density–
weighted MRI. Additional fast imaging with steady-state precession (FISP) 
images were required in order to exclude cysts from the tumor volume cal-
culations, and all images were processed using Bruker ParaVision software. 
The total tumor volume of each tumor was calculated from the resulting 
images by multiplying the pixel volume by the number of pixels within 
while not proven, would predict that modulating the consequence 
of chronic efferocytosis, through targeted inhibition of MerTK, 
would increase IL-12 levels, decrease IL-10 levels, increase tumor 
CD8+ T lymphocytes, and decrease malignant progression. How-
ever, this hypothesis remains to be tested, requiring a systematic 
evaluation of efferocytosis in the tumor microenvironment. We 
did not observe major differences in apoptotic material in the 
microenvironment of MerTK+/+ and MerTK–/– mice in late-stage 
tumors (Supplemental Figure 1). However, dramatic differences 
in apoptotic cell numbers are only seen in acute challenges in 
MerTK–/– mice (23). Other macrophage receptors eventually clear 
apoptotic material, but these alternative clearance mechanisms do 
not suppress the inflammatory response to the extent that MerTK 
does. This conclusion is substantiated by the autoimmune pheno-
type seen in the MerTK–/– mice.
IL-12 stimulates antitumor immunity in several models of epi-
thelial tumors in part by promoting CD8+ T lymphocyte expansion 
(43). Because MerTK suppresses IL-12 production in the tumor 
microenvironment, MerTK signaling may suppress antitumor 
immunity through suppression of CD8+ T lymphocyte prolifera-
tion. Consistent with this idea, we found that depletion of CD8+ T 
lymphocytes restored tumor growth in the MerTK-deficient tumor 
microenvironment. In the case of AXL/TYRO3/MerTK triple-defi-
cient mice, sustained IL-12 levels in normal tissues correlated with 
increased presence of CD8+ T lymphocytes and induction of adap-
tive immunity against self-antigens (21). While this response would 
be undesirable in normal tissues, immunity against tumor-specific 
antigens may improve the outcome of patients with cancer. This is 
supported by increasing evidence gained by expression microarrays 
that correlates tumors bearing a Th1 (e.g., IL-6, IL-12, CD8, gran-
zyme B) gene expression signature with an improved outcome over 
tumors bearing a Th2 (e.g., IL-10, TGF-β, IL-4, cathepsin, IL-13, 
CD4) signature (38, 52, 53). Recent work has shown that tumors 
can orchestrate the immune response in a manner advantageous 
for tumor growth, metastasis, and escape from immune surveil-
lance (54). The present data suggest that inhibition of MerTK sig-
naling may be a promising therapeutic intervention that can break 
the deleterious immune suppression cycle by directly targeting 
the tumor-associated innate immune system. This could shift the 
immune response toward a more favorable antitumor one. MerTK 
inhibition that would set the stage for an antitumor Th1 response 
combined with new clinical agents designed to prolong antitumor 
T cell action may well provide an additive antitumor effect.
Methods
Mice. All mice regardless of genotype were inbred to C57BL/6 for at least 
10 generations. MerTK–/– mice, originally referred to as MerKD mice, have 
been previously described (30).To generate MerTK+/+ and MerTK–/– siblings, 
MerTK+/– males and females were mated to generate the expected Mende-
lian ratios of offspring, which were genotyped using the following primers: 
forward 5′-GAATTTACCTTTCACAGGTTGCGG; reverse 5′-TCGTCAA-
GAAGGCGATAGAAGGCG. Mice were maintained in American Asso-
ciation for Accreditation of Laboratory Animal Care–approved animal 
facilities at the University of North Carolina under an approved IACUC 
protocol. Where indicated, mice were treated with BrdU (10 mg/kg in ster-
ile PBS) by i.p. injection 1 hour prior to tissue collection.
Transplantation of tumor cells. Primary mammary tumor cells were derived 
from a female MMTV-PyVmT mouse inbred to C57BL/6 for 6 generations 
as previously described (54). B16:F10 cells were obtained from American 
Type Tissue Culture Collection. For orthotopic injections into the mam-
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Cytokine array. Whole cell lysates were prepared in lysis buffer (50 mM 
HEPES, pH 7.5, 150 mM NaCl, 10 mM EDTA, 10% glycerol, and 1% Tri-
ton X-100) supplemented with phosphatase inhibitors (1 mM Na3VO4 
and 0.1 mM Na2MoO4) and protease inhibitors (Complete Mini, Roche 
Applied Science). Relative protein expression was analyzed on custom 
cytokine arrays, using 100 μg lysates according to the manufacturer’s 
instructions (RayBiotech). The cytokine membranes were quantified by 
densitometric analysis using ImageJ 1.44o (NIH) with the MicroArray 
Profile plug-in (OptiNav).
Antibody-mediated immune-depletion of CD8+ cells. Mice were treated by i.p. 
injection of anti-mouse CD8 antibody (clone 53.6.7, BioXCell) at 2.5 mg/kg 
in sterile PBS twice weekly for 2 weeks prior to inoculation with MMTV-
PyVmT tumor cells and afterward for an additional 4 weeks.
In situ identification of TUNEL-positive cells and macrophage-programming 
markers. Immunofluorescent in situ staining of apoptotic cells in paraf-
fin-embedded tumors and mammary glands was done using the Dead 
End Fluorometric TUNEL system (Promega). Sections were subsequently 
stained with anti–F4/80-PE (Serotec; diluted 1:100) and DAPI. Triple stain-
ing to identify macrophage-programming status was performed using 
antibodies against F4/80-PE (Serotec; diluted 1:100), iNOS-FITC (BD Bio-
sciences; diluted 1:100), and Arginase I-AMCA (Santa Cruz Biotechnology 
Inc.; 1:100) as previously described (57). Images were acquired on a Zeiss 
Axioplan 2 epifluorescent microscope.
Statistics. Data represent the mean ± SEM of all experiments, unless oth-
erwise noted. Statistical significance was calculated by Mantel-Cox test 
(tumor latency), Student’s t test, Student’s t test with Welch’s correction 
for unequal variance (tumor weight, tumor volume), or analysis of variance 
using Prism 5 (GraphPad Software) unless otherwise noted.
Study approval. All studies involving mice were performed with approval 
from the IACUCs of the University of North Carolina, Chapel Hill, North 
Carolina, USA, or the University of Colorado, Anschutz Medical Campus.
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qRT-PCR. Total RNA was isolated using RNeasy (Qiagen) from single 
mammary cell suspensions and from peritoneal lavage collections. Total 
RNA (10 ng) was reverse transcribed with transcript-specific primers 
and then amplified with transcript-specific primers using SyBR Green 
(Invitrogen), according to manufacturer’s instructions, with a temperature 
of 62°C. The following primers and probes were used. Gas6, 5′-TCTTCT-
CACACTGTGCTGTTGCG and 5′-GGTCAGGCAAGTTCTGAACACAT; 
mouse Il12p40, 5′-TTATGTTGTAGAGGTGGACTGG and 5′-TTTCTTTG-
CACCAGCCATGAGC; mouse Il10, 5′-TGGCCCAGAAATCAAGGAGC and 
5′-CAGCAGACTCAATACACACT; mouse Mfge8, forward: 5′-GGGCCT-
GAAGAATAACACGA and 5′-AGGGCAACTTGGACAACAAC; and mouse 
Gapdh, 5′-AACGACCCCTTCATTGAC-3′ and 5′-TCCACGACATACTCAG-
CAC. The CT for each transcript within each sample was corrected for the 
CT of Gapdh within each sample, normalized to the CT of a single sample, 
and converted into relative levels of expression using the δδCT method, 
such that all values are presented as a fold change in reference to a single 
sample. Samples were analyzed 6 times.
ELISA. Serum was collected by cardiac puncture and immediately stored 
in frozen aliquots. Neat serum was analyzed by ELISA for mouse IL-12p70 
(R&D Systems) and IL-6 (R&D Systems) according to manufacturer’s 
directions. Standard curves generated using manufacturer-supplied IL-12 
and IL-6 were used to calculate serum concentrations of each protein.
Flow cytometry. Single cell suspensions of tumors or mammary glands 
were generated by mechanical tissue disruption using razor blades followed 
by 30 minutes in 1 mg/ml collagenase A (Sigma-Aldrich) in DMEM, 10 
minutes in 1 mg/ml dispase (BD Biosciences), 2 minutes in 0.25% trypsin 
(BD Biosciences), and 5 minutes in DNase I (Stem Cell Technologies). Sin-
gle cell splenocyte suspensions were generated by forcing spleens through 
70-μ and 40-μ mesh filters. Cells (1.5 × 106) were blocked with mouse Fcγ 
III/II Receptor Block (BD Biosciences) for 10 minutes prior to 30-minute 
incubation at room temperature with the following fluorescence-conju-
gated BD Pharmingen antibodies (BD Biosciences) diluted 1:200: rat anti-
mouse Thy1 (53-2.1), rat anti-mouse CD8 (53-6.7), rat anti-mouse CD4 
(GK1.5), rat anti-mouse CD3 (500A2), rat anti-mouse CD45 (30F11), 
rat anti-mouse CD11b (M1/70), hamster anti-mouse CD11c (HL3), and 
mouse IgG2a anti-mouse NK1.1 (PK136). Alternatively, splenocytes were 
fixed and permeabilized (BD Cytofix/Cytoperm, BD Biosciences), DNA 
was denatured using 1 M HCl for 15 minutes, and cells were stained with 
FITC-conjugated anti-BrdU antibody (1:100, BD Biosciences) for 1 hour. 
Cells were washed and counterstained with propidium iodide. Cells were 
analyzed at the UNC Flow Cytometry Core Facility on a Cytek-modified 
5-color FACSCalibur using hardware single-color compensation.
Tumor-associated macrophage isolation. CD11b+ tumor-associated macro-
phages were isolated from freshly digested (serum-free DMEM with 0.1% 
Collagenase I [Sigma-Aldrich] and DNaseI [EMD Millipore] at 37°C for 45 
minutes) single cell suspensions, which were enriched using CD11b mag-
netic beads (Miltenyi Biotec) and MS Columns (Miltenyi Biotec) according 
to the manufacturer’s directions.
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